Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Metagenomi
Biotech
Moderna exits Metagenomi gene editing deal worth $3B biobucks
Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting a partnership worth up to $3 billion in biobucks.
Gabrielle Masson
May 1, 2024 4:00pm
Biotech's top money raisers: 2023
Feb 26, 2024 5:00am
Metagenomi, Telomir offer double test case for preclinical IPOs
Feb 9, 2024 7:00am
Kyverna raises IPO expectations to almost $300M
Feb 6, 2024 9:46am
Gene editing biotech Metagenomi plans modest $87M IPO
Feb 5, 2024 9:14am
Arrivent unveils $135M IPO pricing to get furmonertinib to FDA
Jan 22, 2024 10:28am